Editorial the future role of NICE

BMJ (Online)

Volumn 341, Issue 7781, 2010, Pages 1006-

  Maynard, Alan ^a   Bloor, Karen ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; EDITORIAL; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; MASS MEDIUM; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; CHILD; CHILD WELFARE; FORECASTING; GOVERNMENT; HUMAN; INTERNATIONAL COOPERATION; ORGANIZATION; UNITED KINGDOM;

ACADEMIES AND INSTITUTES; CHILD; CHILD WELFARE; FORECASTING; GOVERNMENT AGENCIES; GREAT BRITAIN; HUMANS; INTERNATIONAL COOPERATION;

EID: 78349301291     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6286     Document Type: Editorial

References (7)

1. Blumenthal D. Doctors and drug companies. N Engl J Med 2004;351:1885-90.
2. Appleby J, Devlin N, Parkin D. NICE's cost-effectiveness threshold. BMJ 2007;335:358.
3. Martin S, Rice N, Smith PC. The link between health spending and health outcomes in the new English primary care trusts. Centre for Health Economics, 2008. www.york.ac.uk/media/che/documents/papers/researchpapers/ CHE%20Research%20Paper%2042.pdf.
4. Department of Health. Equity and excellence: liberating the NHS. 2010. www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-117353.
5. House of Commons Health Committee. National Institute for Health and Clinical Excellence. HC 27-1; 2008.
6. Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed. BMJ 2008;336:251.
7. Office of Fair Trading. The pharmaceutical price regulation scheme. An OFT market study. 2007. www.oft.gov.uk/shared-oft/reports/comp-policy/oft885. pdf.